Zhuhai Danceshi Biopharmaceutical

Danceshi Biopharmaceutical is a biotechnology company based in Zhuhai, China, dedicated to the discovery and development of next-generation precision oncology therapies. The company focuses on the field of synthetic lethality and DNA damage repair (DDR), leveraging a proprietary platform to identify novel therapeutic targets. Its primary research efforts are directed toward developing small molecule inhibitors, including highly selective PARP1 inhibitors and DNA polymerase theta (POLQ) inhibitors. These programs aim to treat various solid tumors, particularly those that have developed resistance to existing PARP inhibitor therapies. Founded in 2021, the company has attracted significant investment from prominent venture capital firms to accelerate its pipeline toward clinical trials. Danceshi's approach combines deep biological insights with advanced screening technologies to address significant unmet needs in the global oncology market.